Morgan Stanley’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Morgan Stanley’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.51M	Buy	96,777 +21,860	+29%	+$562K	﹤0.01%	4603
2025 Q4	$1.72M	Buy	+74,917	New	+$1.3M	﹤0.01%	4908
2025 Q1	–	Sell	-100	Closed	-$465	–	8135
2024 Q4	$465	Sell	100 -60	-38%	-$392	﹤0.01%	7350
2024 Q3	$1.94K	Buy	160 +40	+33%	+$522	﹤0.01%	7136
2024 Q2	$1.42K	Sell	120 -160	-57%	-$2.53K	﹤0.01%	7111
2024 Q1	$5.46K	Buy	+280	New	+$4.98K	﹤0.01%	6869
2023 Q4	–	Hold	0	–	–	–	7806
2023 Q3	–	Hold	0	–	–	–	7601
2022 Q2	–	Sell	-23	Closed	-$1K	–	7866
2022 Q1	$1K	Buy	+23	New	+$1.29K	﹤0.01%	7841
2021 Q4	–	Hold	0	–	–	–	8020
2021 Q3	–	Sell	-4	Closed	-$1K	–	7965
2021 Q2	$1K	Buy	+4	New	+$545	﹤0.01%	7612
2021 Q1	–	Sell	-40	Closed	-$13K	–	7511
2020 Q4	$13K	Buy	+40	New	+$14.9K	﹤0.01%	6564

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Morgan Stanley's DMRA Position: Q1 2026 in Review

Morgan Stanley increased its Damora Therapeutics, Inc. Ordinary Shares (DMRA) stake by 29% in Q1 2026, buying an estimated $562K and bringing the position to 96,777 shares worth $2.51M. The position accounts for ﹤0.01% of the portfolio, ranked #4603.

Morgan Stanley first reported a position in DMRA in Q4 2020 and has held it in 9 quarters since. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

Morgan Stanley held 96,777 shares of Damora Therapeutics, Inc. Ordinary Shares worth $2.51M as of Q1 2026.
Morgan Stanley bought 21,860 Damora Therapeutics, Inc. Ordinary Shares shares in Q1 2026, an estimated $562K.
Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4603 holding.
Morgan Stanley first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q4 2020 and has held it in 9 quarters since.
65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.